Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.60 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.60 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HTR1D | P28221 | 1/20 | 0.55 |
| ▸ | HTR1B | P28222 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17193571 | 0.89 | TSHR (0.59) | TSHRCARM1PRMT6PRMT8SMN1; SMN2 | |
| SCHEMBL11795494 | 0.89 | LMNA (0.62) | TSHRCARM1PRMT6PRMT8SMN1; SMN2 | |
| SCHEMBL7323463 | 0.87 | SIGMAR1 (0.64) | TSHRCARM1PRMT6PRMT8SIGMAR1 | |
| SCHEMBL11315356 | 0.85 | TSHR (0.50) | TSHRCARM1PRMT6PRMT8SMN1; SMN2 | |
| SCHEMBL13136911 | 0.85 | TSHR (0.61) | TSHRCARM1PRMT6PRMT8SMN1; SMN2 | |
| SCHEMBL7055109 | 0.83 | CARM1 (0.75) | TSHRCARM1PRMT6PRMT8SMN1; SMN2 | |
| SCHEMBL15806390 | 0.82 | KCNH2 (0.59) | SIGMAR1 | |
| SCHEMBL12474 | 0.82 | PYCR1 (0.50) | TSHRCARM1PRMT6PRMT8SMN1; SMN2 | |
| SCHEMBL7235029 | 0.82 | TSHR (0.58) | TSHRCARM1PRMT6PRMT8SMN1; SMN2 | |
| SCHEMBL8281042 | 0.82 | MEN1 (0.51) | TSHRCARM1PRMT6PRMT8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | claimed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | claimed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | claimed |
| US-20230142285-A1 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| WO-2019215426-A1 | PROCESS FOR FORMING A CARBON-CARBON BOND | THE UNIVERSITY OF MANCHESTER (GB) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019215427-A1 | PROCESS FOR FORMING A CARBON-CARBON BOND | THE UNIVERSITY OF MANCHESTER (GB) | 2019-11-14 | — | — | WO | disclosed |
| EP-3150608-A1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | Gilead Sciences, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8466287-B2 | Process for producing tricyclic ketone | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2013-06-18 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20090023927-A1 | Process for producing tricyclic ketone | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1900740-A1 | PROCESS FOR PRODUCING TRICYCLIC KETONE | Kabushiki Kaisha Yakult Honsha (JP) | 2008-03-19 | — | — | EP | disclosed |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-0819000-A4 | NODULISPORIC ACID DERIVATIVES | MERCK & CO INC (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-0819000-A1 | NODULISPORIC ACID DERIVATIVES | Merck & Co., Inc. (US) | 1998-01-21 | — | — | EP | disclosed |
| US-4751228-A | 1,6-naphthyridine derivatives | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1988-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | NFKBIA, IKBKG, NFKB2 | TSHR 4787/4885CARM1 2006/4885PRMT6 532/4885 |
| US-20230142285-A1 | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES | MLLT1, MEN1, MLLT3 | TSHR 3952/4885CARM1 1053/4885PRMT6 949/4885 |
| US-20090023927-A1 | Process for producing tricyclic ketone | TKT, DCK, COASY | TSHR 3783/4885CARM1 2193/4885PRMT6 3463/4885 |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | TSHR 3583/4885CARM1 145/4885PRMT6 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.